Accepted Abstracts

ABSTRACT NO. ABSTRACT TITLE ABSTRACT TOPIC SALUTATION FIRST NAME LAST NAME
ASVAC 1001

Persistence of protective anti polio antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, Alum adjuvanted dose sparing inactivated polio vaccine

Polio Dr. Hans- Henrik Kristensen
ASVAC 1003

Vaccination Hesitancy On Childhood Vaccinations During COVID-19 Pandemic In A Tertiary Hospital: A Cross-Sectional Study

Vaccines in specific settings Dr. Jennica Alexis Algas
ASVAC 1013

Knowledge and Attitudes Perceived by Junior High School Students on COVID-19 vaccines in a Private and a Public High School in Tarlac City

Vaccines in specific settings Ms. Maria Rosario Gaspar
ASVAC 1017

Evaluating the immunogenicity, efficacy, and safety of TAK-003 by age group: an analysis of the DEN-301 phase 3 clinical trial

Mosquito-borne viruses e.g Dengue, Japanese encephalitis, Zika, Malaria and Chikungunya Dr. Jennifer Feliciano
ASVAC 1020

COVID-19 Vaccine Effectiveness Research in Southeast Asia: Current Capability Using Secondary Data

Disease-specific vaccines Dr. Anne-Frieda Taurel
ASVAC 1021

Presenteeism: The Reality to be Discussed With COVID-19 Vaccine Recipients

Respiratory viruses e.g Influenza, Respiratory Syncytial virus Dr. Seth Toback
ASVAC 1024

Safety and immunogenicity of a bivalent omicron BA.4/BA.5 vaccine against COVID-19

Disease-specific vaccines Dr. Spyros Chalkias
ASVAC 1025

Burden and Impact of Reactogenicity Among United States and Canadian Adults Receiving COVID-19 Vaccines: Vaccine Impact on Productivity (VIP) Study

Respiratory viruses e.g Influenza, Respiratory Syncytial virus Dr. Matthew Rosculp
ASVAC 1026

How Much of a Burden Is Vaccine-Related Reactogenicity? Results from a 6-Day Symptom Diary Among United States and Canadian Adults Receiving COVID-19 Vaccines

Respiratory viruses e.g Influenza, Respiratory Syncytial virus Dr. Matthew Rosculp
ASVAC 1030

Remaining Lifetime Burden of Herpes Zosters and Public Health Impact of Adjuvanted Recombinant Zoster Vaccine among Adults ≥50 Years in Five Countries in Southeast Asia

Evidenced-based introduction of new vaccines Dr. Ru Han
ASVAC 1033

TAK-003 dengue vaccine clinical experience: an integrated analysis of safety data by baseline serostatus

Mosquito-borne viruses e.g Dengue, Japanese encephalitis, Zika, Malaria and Chikungunya Dr. Steven Stockton
ASVAC 1034

The indirect costs and burden of vaccine preventable cancers mortality in Asia-Pacific countries

Disease-specific vaccines Dr. Rosculp Bencina
ASVAC 1035

An open-label, phase 2 study evaluating cell-mediated immune response and safety of a tetravalent dengue vaccine in children and adolescents aged 4–16 years

Mosquito-borne viruses e.g Dengue, Japanese encephalitis, Zika, Malaria and Chikungunya Dr. Sanja Mandaric
ASVAC 1037

A case of invasive pneumococcal disease by non-vaccine serotype 15C.

Disease-specific vaccines Dr. Shu Ting Tammie Seethor
ASVAC 1038

MesVaccins.net: A New Digital Vaccination Card to Empower People and Healthcare Professionals

Monitoring and surveillance Prof. Jean-Louis Koeck
ASVAC 1039

Influenza Associated Acute Necrotizing Encephalopathy (ANEC) and the role of Influenza Vaccination: A Case Study

Respiratory viruses e.g Influenza, Respiratory Syncytial virus Dr. Mark Goh
ASVAC 1040

Salmonella-delivered COBRA-HA1 antigen derived from H1N1 hemagglutinin sequences elicits broad-spectrum protection against influenza A subtypes

Respiratory viruses e.g Influenza, Respiratory Syncytial virus Prof. John Hwa Lee
ASVAC 1041

Novel pro-and eukaryotic expression plasmid expressing omicron antigens delivered via Salmonella elicited MHC class I and II based protective immunity

Vaccines in development Prof. John Hwa Lee
ASVAC 1042

Salmonella-mediated oral delivery of multiple-target vaccine constructs with conserved and variable regions of SARS-CoV-2 protect against the Delta and Omicron variants in hamster

Vaccines in development Prof. John Hwa Lee
ASVAC 1044

Relative effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines in adults at higher risk for severe COVID-19 outcomes

Disease-specific vaccines Dr. Van Hung Nguyen
ASVAC 1046

Capabilities, Post-Coup And Cataclysm; covid-19 Vaccine Acceptance And Its Determinants Among Myanmar Migrant Workers In Southern Thailand, Myanmar’s Responses To Covid-19

Targeted vaccination strategies Dr. Aung Tan Oo
ASVAC 1047

Factors Associated with Death in Adult COVID-19 Patients Admitted to Two Referral Hospitals in the Philippines

Disease-specific vaccines Dr. Jude Raphael Lo
ASVAC 1048

Assessment Of Maternal Knowledge, Attitudes, And Perceptions On HPV Vaccination For Females Aged 9-17 Years In Calamba City, Laguna

Vaccines in specific settings Ms. Maria Teresa Bsilides
ASVAC 1052

Interchangeability of Pneumococcal Conjugate Vaccines in Children – Systematic Review and Meta Analysis

Vaccine Implementation Dr. John Andrew Caposano
ASVAC 1055

Effect of Web-based Short Message Service (SMS) Reminders on Vaccination Coverage and Timeliness of Routine Immunizations Among Infants in Baguio City: A Randomized Controlled Trial

Targeted vaccination strategies Dr. Karla Rigos
ASVAC 1056

Australia’s rotavirus immunisation program: impact on acute gastroenteritis hospitalisations over 13 years

Enteric Vaccines e.g. Cholera, Typhoid and Rotavirus Dr. Aditi Dey
ASVAC 1057

Acceptance Of COVID-19 Vaccination Among Children Who Were Eligible to Receive CYD-TDV In 2017 In Cebu, Philippines

Vaccines in specific settings Ms. Anna Maureen Cuachin
ASVAC 1058

Do you speak vaccines? Proposal for a structured global terminology on vaccines

Monitoring and surveillance Prof. Jean-Louis Koeck
ASVAC 1059

Standardization and Harmonization of COVID-19 Case and Vaccination Data in Selected Philippine Cohorts

Monitoring and surveillance Mr. Arturo Jr. Ongkeko
ASVAC 1060

The Philippine COVID-19 Vaccine Effectiveness Project

Vaccines in specific settings Dr. Regina Berba